JOHANNESBURG, July 21 (Reuters) – South Africa’s health regulator is reviewing 12 applications for generic versions of semaglutide, the active ingredient in Novo Nordisk’s blockbuster diabetes and weight-loss medicines, it said on Tuesday.
South Africa regulator reviews 12 generic semaglutide applications
By Ghana News